AU2005275183B2 - Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses - Google Patents

Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses Download PDF

Info

Publication number
AU2005275183B2
AU2005275183B2 AU2005275183A AU2005275183A AU2005275183B2 AU 2005275183 B2 AU2005275183 B2 AU 2005275183B2 AU 2005275183 A AU2005275183 A AU 2005275183A AU 2005275183 A AU2005275183 A AU 2005275183A AU 2005275183 B2 AU2005275183 B2 AU 2005275183B2
Authority
AU
Australia
Prior art keywords
methyl
ethyl
pyrrolidin
oxazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005275183A
Other languages
English (en)
Other versions
AU2005275183A1 (en
Inventor
Lisa Selsam Beavers
Serge Louis Boulet
Terry Patrick Finn
Robert Alan Gadski
William Joseph Hornback
Cynthia Darshini Jesudason
Richard Todd Pickard
Freddie Craig Stevens
Grant Matthews Vaught
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2005275183A1 publication Critical patent/AU2005275183A1/en
Application granted granted Critical
Publication of AU2005275183B2 publication Critical patent/AU2005275183B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2005275183A 2004-07-26 2005-07-14 Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses Ceased AU2005275183B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59119104P 2004-07-26 2004-07-26
US60/591,191 2004-07-26
PCT/US2005/024883 WO2006019833A1 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses

Publications (2)

Publication Number Publication Date
AU2005275183A1 AU2005275183A1 (en) 2006-02-23
AU2005275183B2 true AU2005275183B2 (en) 2011-03-17

Family

ID=35134220

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005275183A Ceased AU2005275183B2 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses

Country Status (17)

Country Link
US (1) US7666871B2 (de)
EP (1) EP1786790B1 (de)
JP (1) JP4982367B2 (de)
CN (1) CN1989115B (de)
AT (1) ATE432926T1 (de)
AU (1) AU2005275183B2 (de)
BR (1) BRPI0513777A (de)
CA (1) CA2575081C (de)
CY (1) CY1109493T1 (de)
DE (1) DE602005014786D1 (de)
DK (1) DK1786790T3 (de)
ES (1) ES2325865T3 (de)
MX (1) MX2007001029A (de)
PL (1) PL1786790T3 (de)
PT (1) PT1786790E (de)
SI (1) SI1786790T1 (de)
WO (1) WO2006019833A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
WO2006089076A2 (en) 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
US7790720B2 (en) 2005-03-31 2010-09-07 Ucb Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
KR101439557B1 (ko) 2005-11-15 2014-09-11 오츠카 세이야쿠 가부시키가이샤 옥사졸 화합물 및 제약 조성물
MX2008011791A (es) 2006-03-15 2008-09-25 Wyeth Corp Azaciclilaminas-n-sustituidas como antagonistas de histamina-3.
EP2024327A1 (de) * 2006-05-19 2009-02-18 Basf Se Benzoylsubstituierte alanine
CN101432261A (zh) 2006-05-19 2009-05-13 惠氏公司 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
CA2693138A1 (en) * 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
WO2009126782A1 (en) * 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US8383829B2 (en) * 2008-04-15 2013-02-26 Konica Minolta Holdings, Inc. Electrochromic compound, electrode, and display element
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
MX2012015102A (es) 2010-07-06 2013-05-01 Astrazeneca Ab Agentes terapeuticos 976.
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6307096B2 (ja) 2013-01-23 2018-04-04 アストラゼネカ アクチボラグ 化合物
JP6807841B2 (ja) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
EP3319968A1 (de) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclische n-aminophenyl-amide als inhibitoren der histondeacetylase
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
PT3664802T (pt) 2017-08-07 2022-05-24 Alkermes Inc Inibidores bicíclicos de histona-desacetilase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
WO2005040158A1 (en) * 2003-10-24 2005-05-06 F. Hoffmann - La Roche Ag 1-′(e)-2-(phenyl) ethenyl-4-(arylalkoxy)-oxazole or - thiazole compounds as her-2 tyrosine kinases inhibitors and their use in the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU674613B2 (en) * 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
AU3957600A (en) * 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
CA2441080A1 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
JP4597524B2 (ja) 2002-02-01 2010-12-15 ハイ・ポイント・ファーマスーティカルズ、エルエルシー アミノアルキル置換されたアゼチジン、ピロリジン、ピペリジン、およびアゼパンのアミド
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
WO2005040158A1 (en) * 2003-10-24 2005-05-06 F. Hoffmann - La Roche Ag 1-′(e)-2-(phenyl) ethenyl-4-(arylalkoxy)-oxazole or - thiazole compounds as her-2 tyrosine kinases inhibitors and their use in the treatment of cancer

Also Published As

Publication number Publication date
US20070197604A1 (en) 2007-08-23
CY1109493T1 (el) 2014-08-13
CA2575081A1 (en) 2006-02-23
PT1786790E (pt) 2009-08-18
EP1786790A1 (de) 2007-05-23
JP2008507579A (ja) 2008-03-13
AU2005275183A1 (en) 2006-02-23
DE602005014786D1 (de) 2009-07-16
BRPI0513777A (pt) 2008-05-13
ES2325865T3 (es) 2009-09-22
WO2006019833A1 (en) 2006-02-23
CN1989115A (zh) 2007-06-27
SI1786790T1 (sl) 2009-10-31
ATE432926T1 (de) 2009-06-15
EP1786790B1 (de) 2009-06-03
US7666871B2 (en) 2010-02-23
PL1786790T3 (pl) 2009-10-30
DK1786790T3 (da) 2009-07-20
CA2575081C (en) 2013-05-07
CN1989115B (zh) 2012-03-21
JP4982367B2 (ja) 2012-07-25
MX2007001029A (es) 2007-04-12

Similar Documents

Publication Publication Date Title
AU2005275183B2 (en) Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses
AU2005277518B2 (en) Histamine H3 receptor agents, preparation and therapeutic uses
WO2007126043A1 (ja) チアゾール環を含むカルボン酸誘導体の医薬用途
US11046680B1 (en) Heteroaryl-substituted triazoles as APJ receptor agonists
EP3122721A1 (de) Ror-gamma-modulatoren und verwendungen davon
WO2006049232A1 (ja) チアゾール環を含むカルボン酸誘導体およびその医薬用途
JP2016135778A (ja) シアノトリアゾール化合物の医薬用途
WO2007078523A2 (en) 5-phenyl-3-benzyl-0xaz0lidin-2-0ne derivatives and related compounds as metabotropic glutamate receptor potentiators for the treatment of neurological and psychiatric disorders
JP2011506521A (ja) トリアゾ−ル置換アリールアミド誘導体およびp2x3および/またはp2x2/3プリン受容体アンタゴニストとしてのそれらの使用
CA2510793A1 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
BG108597A (bg) Антидиабетични средства за орално приложение
EP2459554B1 (de) Substituierte benzamidderivate als glucokinase (gk)-aktivatoren
MX2015002624A (es) Nuevas tiofenilamidas no anuladas como inhibidores de las proteinas de union a acido graso (fabp) 4 y/o 5.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired